New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 1, 2013
06:01 EDTLH, BMYLabCorp Clinical Trials selected as preferred provider by Bristol-Myers
LabCorp (LH) announced that LabCorp Clinical Trials has been selected as a preferred provider for full-service global central laboratory services and biomarker testing by Bristol-Myers (BMY). The five-year agreement builds on a long-standing partnership between the two companies during which LabCorp's global central lab, biomarker and specialty testing capabilities have supported various Bristol-Myers Squibb early and late-stage clinical development programs.
News For LH;BMY From The Last 14 Days
Check below for free stories on LH;BMY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 21, 2014
08:09 EDTLHLabCorp price target raised to $130 from $120 at Maxim
Subscribe for More Information
06:43 EDTBMYGrowing market for hepatitis-C treatment prompts legal scramble, WSJ says
Subscribe for More Information
July 18, 2014
12:04 EDTLHLabCorp pullback a buying opportunity, says Maxim
Subscribe for More Information
11:25 EDTLHPiper awaits notable volume recovery to get more positive on LabCorp
Piper Jaffray views LabCorp's in-line quarter as positive and said restored TRICARE coverage may provide added upside, but the firm would like to see notable lab volume recovery and a pullback in the shares before becoming more positive on the stock. Piper raised its price target on the stock to $99 from $98 and maintains its Neutral rating on LabCorp.
06:43 EDTLHLabCorp raises FY14 adjusted EPS to $6.50-$6.75 from $6.40-$6.70
Subscribe for More Information
06:43 EDTLHLabCorp: Q2 sales increase due to test volume
Total test volume increased 5.3%, while revenue per requisition decreased 2.0% due to test and payer mix. Reports Q2 operating income $246.7M, operating cash flow $207.4M, free cash flow $159M
06:41 EDTLHLabCorp reports Q2 adjusted EPS $1.84, consensus $1.77
Subscribe for More Information
July 17, 2014
09:34 EDTLHLabCorp upgraded to Outperform from Market Perform at William Blair
Subscribe for More Information
08:08 EDTBMYBristol-Myers, Pfizer announce enrollment in Phase IV EMANATE trial for Eliquis
Subscribe for More Information
July 16, 2014
06:26 EDTBMYBristol-Myers lung cancer trials being underestimated, says Citigroup
After building a statistical model of Bristol-Myers' two critical registration trials for Opdivo in lung cancer, Citigroup believes the market is "materially" underestimating both Phase III trials. Citi says potential Opdivo FDA approval in 2015 in lung cancer would give Bristol-Myers an up to two year lead time versus Merck (MRK) and Roche (RHHBY). The firm estimates 2023 Opdivo revenue at $7B and reiterates a Buy rating on Bristol with a $60 price target.
July 15, 2014
11:13 EDTBMYPerrigo retreats after analyst sees limited potential buyers
Subscribe for More Information
07:35 EDTBMYPerrigo potential buyers list could be limited, says Jefferies
After Globes reported that Perrigo retained an investment bank to assist with a potential merger, Jefferies says the list of potential buyers could be limited since the store brand business is fundamentally a high volume, lower margin model. The firm notes U.S. companies that currently do not have large over-the-counter divisions include Bristol-Myers (BMY), Eli Lilly (LLY) and Merck (MRK). Jefferies views the merger speculation surrounding Perrigo as not surprising given the company's strong long-term fundamentals and attractive Irish domicile. It has a Buy rating on the stock with a $160 price target.
July 14, 2014
08:59 EDTLHLabCorp management to meet with Maxim
Field trip to company lab to be held in New Jersey on July 15 hosted by Maxim.
July 10, 2014
12:43 EDTBMYBristol-Myers announces plans for Q3 submission of Opdivo BLA
Bristol-Myers Squibb announced earlier that, following discussions with the FDA, the company is planning a Q3 submission of a Biologics Licensing Application for Opdivo for previously treated advanced melanoma. This will mark the second tumor type for which Bristol-Myers Squibb has a regulatory submission underway for Opdivo in the U.S. We continue to collaborate closely with the FDA on Opdivo and the planned submission in advanced melanoma represents an important step forward in our companys commitment to deliver innovative treatment options for patients with cancer, said Michael Giordano, MD, Head of Oncology Development, Bristol-Myers Squibb. The advanced melanoma BLA is based on data from Checkmate -037, a multinational, multicenter, randomized open-label Phase 3 trial evaluating Opdivo compared to dacarbazine or carboplatin/paclitaxel in patients with unresectable or metastatic melanoma who have been previously treated with Yervoy and, if BRAF-mutation positive, a BRAF inhibitor regimen. Bristol-Myers Squibb has proposed the name Opdivo, which, if approved by health authorities, will serve as the trade name for nivolumab.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use